These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28862945)

  • 41. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration.
    Franch-Nadal J; Roura-Olmeda P; Benito-Badorrey B; Rodriguez-Poncelas A; Coll-de-Tuero G; Mata-Cases M;
    Fam Pract; 2015 Feb; 32(1):27-34. PubMed ID: 25194144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing variability in compliance with recommendations given by the International Diabetes Federation (IDF) for patients with type 2 diabetes in primary care using electronic records. The APNA study.
    Brugos-Larumbe A; Aldaz-Herce P; Guillen-Grima F; Garjón-Parra FJ; Bartolomé-Resano FJ; Arizaleta-Beloqui MT; Pérez-Ciordia I; Fernández-Navascués AM; Lerena-Rivas MJ; Berjón-Reyero J; Jusué-Rípodas L; Aguinaga-Ontoso I
    Prim Care Diabetes; 2018 Feb; 12(1):34-44. PubMed ID: 28732655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System.
    Benedict AW; Spence MM; Sie JL; Chin HA; Ngo CD; Salmingo JF; Vidaurreta AT; Rashid N
    J Manag Care Spec Pharm; 2018 Feb; 24(2):114-122. PubMed ID: 29384029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between medication adherence and clinical outcomes in patients with chronic kidney disease: a prospective cohort study.
    Tangkiatkumjai M; Walker DM; Praditpornsilpa K; Boardman H
    Clin Exp Nephrol; 2017 Jun; 21(3):504-512. PubMed ID: 27438073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease.
    Kim MK; Han K; Joung HN; Baek KH; Song KH; Kwon HS
    Cardiovasc Diabetol; 2019 Oct; 18(1):139. PubMed ID: 31640795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Shi X; He J; Lin M; Liu C; Yan B; Song H; Wang C; Xiao F; Huang P; Wang L; Li Z; Huang Y; Zhang M; Chen CS; Obst K; Li W; Yang S; Yao G; Li X
    Am Heart J; 2021 Aug; 238():45-58. PubMed ID: 33957103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States.
    Lu Y; Wang P; Zhou T; Lu J; Spatz ES; Nasir K; Jiang L; Krumholz HM
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29374046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP.
    Wens J; Gerard R; Vandenberghe H
    Prim Care Diabetes; 2011 Apr; 5(1):19-24. PubMed ID: 21030327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
    Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
    Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.
    Mete M; Wilson C; Lee ET; Silverman A; Russell M; Stylianou M; Umans JG; Wang W; Howard WJ; Ratner RE; Howard BV; Fleg JL
    J Diabetes Complications; 2011; 25(6):362-7. PubMed ID: 21775166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
    Pais P; Jung H; Dans A; Zhu J; Liu L; Kamath D; Bosch J; Lonn E; Yusuf S
    Eur J Prev Cardiol; 2019 May; 26(7):681-697. PubMed ID: 30537846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status.
    Wong ND; Patao C; Wong K; Malik S; Franklin SS; Iloeje U
    Diab Vasc Dis Res; 2013 Nov; 10(6):505-13. PubMed ID: 23975724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.
    Gitt AK; Schmieder RE; Duetting E; Bramlage P; Schneider S; Tschöpe D;
    Cardiovasc Diabetol; 2012 Dec; 11():148. PubMed ID: 23216660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.
    Kuznik A; Mardekian J
    Cardiovasc Diabetol; 2011 Apr; 10():31. PubMed ID: 21496321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood pressure, low-density lipoprotein cholesterol, and incidences of coronary artery disease and ischemic stroke in Japanese: the Suita study.
    Tsukinoki R; Okamura T; Watanabe M; Kokubo Y; Higashiyama A; Nishimura K; Takegami M; Murakami Y; Okayama A; Miyamoto Y
    Am J Hypertens; 2014 Nov; 27(11):1362-9. PubMed ID: 24713850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Faggiano P; Fattirolli F; Frisinghelli A; Piccioli L; Dasseni N; Silverii MV; Albricci L; D'Ambrosio G; Garrì R; Esposito L; Giallauria F
    Monaldi Arch Chest Dis; 2019 May; 89(2):. PubMed ID: 31107039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.